| ABBV |
AbbVie Inc. |
92%
|
upfront and milestone payments under our collaboration and license agreements with AbbVie |
| ABBV |
AbbVie Inc. |
92%
|
Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO graph: upfront and milestone payments under … |
| F-HOFFMANN-LA-ROCHE-LTD |
F-HOFFMANN-LA-ROCHE-LTD |
90%
|
development event payments under our co-funded clinical trial collaboration with F. Hoffmann-La Roche Ltd, or Roche |
| GILEAD |
GILEAD |
90%
|
upfront and milestone payments under our collaboration and license agreements with Gilead |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from XLO graph: ction with creating an independent sale… |
| AZN |
AstraZeneca PLC |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from XLO graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from XLO graph: Reciprocal relationship from CE… |
| CELG-RI |
CELG-RI |
72%
|
voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making… |
| GILD |
Gilead Sciences, Inc. |
72%
|
t and the stock purchase agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The Company accounted for the common stock … |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from XLO graph: Reciprocal relationship from GILD graph: Reciprocal relationship from XLO graph: Reciprocal relationship from GILD gra… |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
Reciprocal relationship from JANX graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization req… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requ… |
| JNJ |
Johnson & Johnson |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| PDSB |
PDS Biotechnology Corporation |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| PDSB |
PDS Biotechnology Corporation |
72%
|
Reciprocal relationship from PDSB graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization req… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from REGN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from REGN gra… |
| SNYNF |
Sanofi |
72%
|
al advantages compared to alternative treatments; • the prevalence and severity of any side effects; • the product’s convenience and ease of administration compared to alternative treatments; • the c… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from XLO graph: al advantages compared to alternative treatments; • the prevalence and severity of any side effects; • the product’s … |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization re… |
| VIR |
Vir Biotechnology, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| VIR |
Vir Biotechnology, Inc. |
72%
|
Reciprocal relationship from VIR graph: Reciprocal relationship from XLO graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XLO graph: Reciprocal relationship from VIR graph:… |
| BMY |
Bristol-Myers Squibb Company |
62%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from XLO graph: cost- effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing appro… |
| COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY |
COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY |
62%
|
cost- effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary … |
| EMERGING-GROWTH-COMPANY |
EMERGING-GROWTH-COMPANY |
62%
|
the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts we would expect to receive for each performance oblig… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
et” offerings; the sale of prefunded warrants in our June 2025 and February 2026 follow-on offerings; the exercise of certain common stock warrants issued in connection with our June 2025 follow-on o… |
